ScreenerHero

SYRSSyros Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · syros.com
0.0004USD+300.00%Mkt Cap: 10732 $P/E: —

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap10.73K $
Enterprise Value1.96M $
Revenue (TTM)386.00K $
Gross Profit-88.25M $
Net Income (TTM)-164.57M $
Revenue/Share0.0100 USD
Last Price0.0004 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.02
EV/Revenue5.08
P/S0.03
P/B-0.00
EPS (TTM)-3.07
EPS (Forward)-2.61
52W Range
0.00012% of range0.0200
52W High0.0200 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin-28891.71%
EBITDA Margin0.00%
Profit Margin-1656.34%
ROE-987.72%
ROA-97.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.71M $
CapEx (TTM)272.00K $
FCF Margin-15011.01%
FCF Yield-539904.03%
Net Debt1.95M $
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity3.73
Current Ratio2.25
Quick Ratio2.05
Book Value/Sh-0.4150 USD
Cash/Share2.172 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 19, 2022
Analyst Consensus
Rating—
Target (Mean)8.750 USD
Upside (mean)+2187400.1%
Target Range4.000 USD – 20.00 USD
$4.000+2187400.1% to mean$20.00
# Analysts4
Ownership
Shares Out.26.83M
Float26.83M
Insiders0.07%
Institutions9.62%
Short Interest
Short Ratio0.8d
Short % Float3.81%
Short % Out.3.50%
Shares Short939.58K
Short (prev mo.)723.20K
Technical
SMA 500.0002 (+163.2%)
SMA 2000.0003 (+31.7%)
Beta1.33
S&P 52W Chg18.16%
Avg Vol (30d)5.14K
Avg Vol (10d)3.58K
Technical Indicators
RSI (14)58.4
MACD0.0000
MACD Signal0.0000
MACD Hist.+0.0000
BB Upper0.0004 USD
BB Middle0.0002 USD
BB Lower-0.0001 USD
BB Width326.91%
ATR (14)0.0002 USD
Vol Ratio (20d)0.32x